Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Mansoor R Mirza,B Benigno,A Dørum,S Mahner,P Bessette, I Bover Barceló,D Berton-Rigaud,J A Ledermann,B J Rimel, J Herrstedt,S Lau,A du Bois,A Casado Herráez,E Kalbacher, J Buscema,D Lorusso,I Vergote,T Levy, P Wang,F A de Jong,D Gupta, U A Matulonis

Gynecologic Oncology（2020）

引用 29|浏览76

暂无评分

摘要

•Long-term safety data for patients from the ENGOT-OV16/NOVA trial is reported.•Grade ≥ 3 thrombocytopenia occurred in 28% of patients in month 1, declining to 9% in month 2.•Dose reductions were highest in month 1 (34%), and declined every month thereafter.•These data support dose reductions according to toxicity criteria and the long-term use of niraparib maintenance treatment.

查看译文

关键词

Niraparib,Long-term safety,Poly(ADP ribose) polymerase inhibitor,Ovarian cancer,Gynecologic oncology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要